KRAS mutation: Should we test for it, and does it matter

Journal of Clinical Oncology

Volumn 31, Issue 8, 2013, Pages 1112-1121

  Roberts, Patrick J ^a   Stinchcombe, Thomas E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; ARRY 438162; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; GDC 0973; GEFITINIB; GEMCITABINE; GI 4000; K RAS PROTEIN; MSC 1936369B; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; PIMASERTIB; PROTEIN TYROSINE KINASE INHIBITOR; REOLYSIN; RETASPIMYCIN; RIDAFOROLIMUS; SELUMETINIB; TAXANE DERIVATIVE; TIVANTINIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SUBSTITUTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; DRUG SAFETY; GENE MUTATION; GENETIC SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SMOKING; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENETIC TECHNIQUES; HUMANS; LUNG NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84875943507     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.0454     Document Type: Review

References (87)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
3. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
5. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
7. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
8. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
9. Kris MG, Johnson BE, Kwiatkowski DJ, et al: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29:477s, 2011 (suppl 15; abstr CRA7506)
10. Mitin N, Rossman KL, Der CJ: Signaling interplay in Ras superfamily function. Curr Biol 15:R563-R574, 2005 (Pubitemid 41026614)
11. Roberts PJ, Der CJ: Targeting the Raf-MEKERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310, 2007 (Pubitemid 46763022)
12. Riely GJ, Kris MG, Marks JL, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. J Clin Oncol 26:425s, 2008 (suppl; abstr 8006)
13. Porta M, Crous-Bou M, Wark PA, et al: Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes. Mutat Res 682:83-93, 2009
14. Al-Mulla F, MacKenzie EM: Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 195:549-556, 2001 (Pubitemid 34030792)
15. Al-Mulla F, Milner-White EJ, Going JJ, et al: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187:433-438, 1999 (Pubitemid 29118275)
16. Span M, Moerkerk PT, De Goeij AF, et al: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69:241-245, 1996 (Pubitemid 26233305)
17. Winder T, Mu ndlein A, Rhomberg S, et al: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21:1283-1287, 2009
18. Ihle NT, Byers LA, Kim ES, et al: Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 104:228-239, 2012
19. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
20. Repasky GA, Chenette EJ, Der CJ: Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14:639-647, 2004 (Pubitemid 39440613)
21. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006 (Pubitemid 44050136)
22. Graziano SL, Gamble GP, Newman NB, et al: Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 17:668-675, 1999 (Pubitemid 29075256)
23. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530, 2001 (Pubitemid 32947838)
24. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al: K-ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos. Int J Cancer 53:250-256, 1993 (Pubitemid 23042874)
25. Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990 (Pubitemid 20260082)
26. Mao C, Qiu LX, Liao RY, et al: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 69:272-278, 2010
27. Gao B, Sun Y, Zhang J, et al: Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol 5:1130-1135, 2010
28. Hunt JD, Strimas A, Martin JE, et al: Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev 11:1405-1412, 2002 (Pubitemid 35340377)
29. Koivunen JP, Kim J, Lee J, et al: Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 99:245-252, 2008
30. Leidner RS, Fu P, Clifford B, et al: Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer. J Clin Oncol 27:5620-5626, 2009
31. Reinersman JM, Johnson ML, Riely GJ, et al: Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6:28-31, 2011
32. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005 (Pubitemid 40425952)
33. Mascaux C, Iannino N, Martin B, et al: The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 92:131-139, 2005 (Pubitemid 40188446)
34. Broermann P, Junker K, Brandt BH, et al: Trimodality treatment in stage III nonsmall cell lung carcinoma: Prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94:2055-2062, 2002 (Pubitemid 34270060)
35. Camps C, Sirera R, Bremnes R, et al: Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 50:339-346, 2005
36. Rodenhuis S, Boerrigter L, Top B, et al: Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study. J Clin Oncol 15:285-291, 1997 (Pubitemid 27020585)
37. Rosell R, Gó mez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158, 1994 (Pubitemid 24026882)
38. Schiller JH, Adak S, Feins RH, et al: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19:448-457, 2001 (Pubitemid 32112858)
39. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005 (Pubitemid 41007845)
40. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005 (Pubitemid 41058345)
41. Zalcman G, Beau-Faller M, Creveuil C, et al: Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer. J Clin Oncol 26:397s, 2008 (suppl; abstr 7500)
42. Shepherd FA, Bourredjem A, Brambilla E, et al: Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. J Clin Oncol 30:453s, 2012 (suppl 15; abstr 7007)
43. Loriot Y, Mordant P, Deutsch E, et al: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6:528-534, 2009
44. Felip E, Rojo F, Reck M, et al: A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14:3867-3874, 2008
45. Han SW, Kim TY, Jeon YK, et al: Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12:2538-2544, 2006
46. Hirsch FR, Varella-Garcia M, Cappuzzo F, et al: Combination of EGFR gene copy number and protein expression predicts outcome for advanced nonsmall-cell lung cancer patients treated with gefitinib. Ann Oncol 18:752-760, 2007 (Pubitemid 46523281)
47. Jackman DM, Miller VA, Cioffredi LA, et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5273, 2009
48. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007 (Pubitemid 46849563)
49. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472-1478, 2008
50. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
51. Roberts PJ, Stinchcombe TE, Der CJ, et al: Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28:4769-4777, 2010
52. Schneider CP, Heigener D, Schott-von-Romer K, et al: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: An analysis of patients from German centers in the TRUST study. J Thorac Oncol 3:1446-1453, 2008
53. van Zandwijk N, Mathy A, Boerrigter L, et al: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro-and prospective observations in non-small-cell lung cancer. Ann Oncol 18:99-103, 2007 (Pubitemid 46152507)
54. Brugger W, Triller N, Blasinska-Morawiec M, et al: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebocontrolled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120, 2011
55. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol 24:5034-5042, 2006 (Pubitemid 46631407)
56. Zhu CQ, da Cunha Santos G, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:4268-4275, 2008
57. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972, 2008
58. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-smallcell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011
59. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
60. Tejpar S, Bokemeyer C, Celik I, et al: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 29:223s, 2011 (suppl 15; abstr 3511)
61. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
62. Stinchcombe TE, Der CJ: Are all KRAS mutations created equal? Lancet Oncol 12:717-718, 2011
63. Garassino MC, Marabese M, Rusconi P, et al: Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 22:235-237, 2011
64. Khambata-Ford S, Harbison CT, Hart LL, et al: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918-927, 2010
65. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
66. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al: Molecular biomarkers in non-small-cell lung cancer: A retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 12:795-805, 2011
67. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
68. Hainsworth JD, Cebotaru CL, Kanarev V, et al: A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 5:1630-1636, 2010
69. Yeh TC, Marsh V, Bernat BA, et al: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576-1583, 2007 (Pubitemid 46450450)
70. Janne PA, Shaw AT, Pereira JR, et al: Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 30:480s, 2012 (suppl 15; abstr 7503)
71. Carretero J, Shimamura T, Rikova K, et al: Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17:547-559, 2010
72. Chen Z, Walton Z, Cheng K, et al: "Co-clinical" trial with genetically-engineered mouse models identifies crucial roles for p53 and Lkb1 in the responses of Kras driven lung cancer to treatment with docetaxel and selumetinib. Nature 483:613-617, 2012
73. Wislez M, Spencer ML, Izzo JG, et al: Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65:3226-3235, 2005 (Pubitemid 40524605)
74. Rivera VM, Squillace RM, Miller D, et al: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 10:1059-1071, 2011
75. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
76. Shapiro G, LoRusso P, Kwak EL, et al: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 29:195s, 2011 (suppl 15; abstr 3005)
77. Kurzrock R, Patnaik A, Rosenstein L, et al: Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). J Clin Oncol 29:215s, 2011 (suppl 15; abstr 3085)
78. Gana-Weisz M, Haklai R, Marciano D, et al: The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 239:900-904, 1997 (Pubitemid 27504200)
79. Riely GJ, Johnson ML, Medina C, et al: A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 6:1435-1437, 2011
80. Eathiraj S, Palma R, Volckova E, et al: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666-20676, 2011
81. Sequist LV, von Pawel J, Garmey EG, et al: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307-3315, 2011
82. Sos ML, Michel K, Zander T, et al: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119:1727-1740, 2009
83. Wong K, Koczywas M, Goldman JW, et al: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29:476s, 2011 (suppl 15; abstr 7500)
84. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932, 2007
85. Mok T, Spigel DR, Park K, et al: Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 28:547s, 2010 (suppl 15; abstr 7537)
86. Bergethon K, Shaw AT, Ignatius Ou S-H, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
87. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012